Clinical Study On Jianpi Huayu Prescription Combined With Bevacizumab And Irinotecan-based Regimen In Patients With Advanced Colorectal Cancer

Objective:Under the guidance of TCM theory and clinical practice,the study was aimed at treating the advanced colorectal cancer patients with Jianpi Huayu prescription combined with bevacizumab and irinotecan-based regimen.By observing the changes of the lesion size,TCM syndrome score,karnofsky scores,serum tumor markers,D-dimer,toxic and side effects in patients to evaluate the role and advantage of Chinese medicine combined with targeted therapy and chemotherapy in the treatment of advanced colorectal cancer.Methods:This study enrolled 60 patients with stage Ⅳ colorectal cancer,patients were divided into experimental group(30 cases of Jianpi Huayu prescription and bevacizumab+CPT-11+ raltitrexed group)and control group(30 cases of bevacizumab+CPT-11+ raltitrexed group).The lesion size,TCM syndrome score,karnofsky score,blood and urine routine,liver and kidney function,coagulation function,toxic and side effects were recorded before and after treatment.The data was statistically analyzed by SPSS 20.Results:1.Comparison of Objective Efficacy:After treatment for 2 cycles,The ORR(10.00%)and DCR(73.33%)in the experimental group of treatment were higher than those in the control group(6.67%and 70.00%).The efficacy of the experimental group was better than the control group,but there was no statistically significant difference between groups(all P>0.05).2.Comparison of TCM syndrome scores:The effective rate of the experimental group after treatment is higher than that of the control group.The difference was statistically significant between the two groups(P<0.05).3.Comparison of the physical condition:the karnofsky score of the experimental group increased significantly after treatment(P<0.05),but control group was decreased.The difference between the two groups was statistically significant(P<0.05).4.Comparison of serum tumor markers:After treatment,the level of CEA and CA199 in the experimental and the control group all decreased after treatment.There was significant difference in CEA levels between the two groups before and after treatment(all P<0.05),but there was no significant difference between the two groups after treatment(P>0.05).There was no significant difference in CA199 levels before and after treatment between the groups(all P>0.05).5.Comparison of serum D-dimer:The D-dimer level in the experimental group was decreased after treatment and compared with the level before treatment,the difference was statistically significant(P<0.05).6.Comparison of Toxicity and safety:The incidences of neutropenia and nausea and vomiting in the experimental group were significantly lower than those in the control group(P<0.05),the remaining indicators were not statistically different.Conclusion:1.Jianpi Huayu prescription combined with bevacizumab+CPT-11+raltitrexed can improve the clinical curative effect,improve karnofsky score,improve TCM syndromes and blood hypercoagulability,its curative effect was better than single target therapy and chemotherapy group,the two groups have similar efficacy in reducing serum CEA and CA199 levels.2.Jianpi Huayu prescription can significantly reduce some adverse reactions of the targeted therapy and chemotherapy,reduce toxic effects,it has good safety.